Clinical efficacy of lysine gluzinc granules in the treatment of persistent diarrhea in infants and young children

doi:10.3877/cma.j.issn.2095-2015.2023.04.013

Abstract

Abstract:

Objective

To observe the clinical efficacy of lysine gluzinc granules in the adjuvant treatment of persistent diarrhea in infants and young children.

Methods

A total of 183 cases of infants and young children with persistent diarrhea admitted to Changsha Maternal and Child Health Care Hospital from January 2018 to June 2022 were selected.Finally a total of 140 cases of infants and young children were included in this study.They were divided into control group and observation group with 70 cases in each group by random number table method.The control group was treated with montelukast, Bifidobacterium tetradecanoides tablets and Shenmue Oral Liquid, while the observation group was treated with lysine gluzinc granules on the basis of the control group.The clinical symptoms, serum immune indexes and clinical efficacy of the two groups were compared before and after treatment, and the occurrence of adverse reactions during the treatment period was recorded.

Results

After treatment, the clinical symptoms and serum immune indexes of children in both groups improved, but the improvement time of clinical symptoms.and hospitalization time.of the observation group were shorter than those of the control group(P<0.05). The serum immune indexes<.and total effective rate.of the observation group were higher than those of the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

Conclusion

Adjuvant treatment with lysine gluzinc granules can effectively relieve the clinical symptoms of infants and young children with persistent diarrhea and enhance the immunity of the children.

Key words: Diarrhea, Infants and young children, Lysine gluzinc granules, Clinical observation

Wenqun Wang. Clinical efficacy of lysine gluzinc granules in the treatment of persistent diarrhea in infants and young children[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 250-253.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2023.04.013

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2023/V13/I04/250

Figures/Tables 5

References 20

1	Hammer HF.Management of Chronic Diarrhea in Primary Care：The Gastroenterologists′ Advice [J]. Dig Dis，2021，39(6)：615-621.
2	Chu C，Rotondo-Trivette S，Michail S．Chronic diarrhea [J]. Curr Probl Pediatr Adolesc Health Care，2020，50(8)：100841.
3	Khurana S，Gur R，Gupta N．Chronic diarrhea and parasitic infections：Diagnostic challenges [J]. Indian J Med Microbiol，2021，39(4)：413-416.
4	Yu M，Jin X，Liang C，et al.Berberine for diarrhea in children and adults：a systematic review and meta-analysis [J]. Therap Adv Gastroenterol，2020，13：1756284820961299.
5	徐雨歆．复方嗜酸乳杆菌片联合赖氨葡锌颗粒治疗小儿轮状病毒性肠炎的效果[J]．中国民康医学，2023，35(10)：83-85.
6	Lo Vecchio A，Conelli ML，Guarino A．Infections and Chronic Diarrhea in Children [J]. Pediatr Infect Dis J，2021，40(7)：e255-e258.
7	Zhu F．Evaluation and Management of Traveler′s Diarrhea in Children [J]. Pediatr Clin North Am，2022，69(1)：99-113.
8	Thiagarajah JR，Kamin DS，Acra S，et al.Advances in Evaluation of Chronic Diarrhea in Infants [J]．Gastroenterology，2018，154(8)：2045-2059.e6.
9	Bandsma RHJ，Sadiq K，Bhutta ZA.Persistent diarrhoea：current knowledge and novel concepts [J]. Paediatr Int Child Health，2019；39(1)：41-47.
10	Iddrisu I，Monteagudo-Mera A，Poveda C，et al.Malnutrition and Gut Microbiota in Children [J]. Nutrients，2021，13(8)：2727.
11	Dian Z，Sun Y，Zhang G，et al.Rotavirus-related systemic diseases：clinical manifestation，evidence and pathogenesis [J]. Crit Rev Microbiol，2021，47(5)：580-595.
12	郭丽霞．脾多肽注射液联合蒙脱石散及双歧杆菌四联活菌片对婴幼儿迁延性慢性腹泻的疗效[J]．河南医学研究，2019，28(13)：2423-2424.
13	刘仙平，王静．葡萄糖酸锌联合双歧杆菌四联活菌片和蒙脱石散治疗迁延性腹泻患儿的疗效[J]．深圳中西医结合杂志，2020，30(20)：156-158.
14	文伟，黄金华，刘燕青等．神曲消食口服液联合锌制剂佐治小儿腹泻50例疗效观察[J]．药品评价，2021，18(01)：44-47.
15	况伶俐，唐耀生，付晓珍，王玲．自拟运脾散联合赖氨葡锌颗粒治疗小儿厌食症的疗效评价[J/OL]．现代医学与健康研究电子杂志，2023，7(9)：97-99.
16	周银，熊超，王胜刚，李洪．布拉氏酵母菌散联合赖氨葡锌颗粒治疗小儿腹泻的疗效及对肠道微生态、胃肠激素的影响[J]．海南医学，2023，34(5)：672-675.
17	张翠，刘青，杨静．赖氨葡锌辅助蒙脱石散治疗小儿急性腹泻临床疗效及对血清炎症因子的影响[J]．黑龙江医药，2022，35(6)：1333-1335.
18	李华年，谢军．加用赖氨葡锌颗粒治疗婴幼儿急性腹泻的临床疗效的研究[J]．江西医药，2021，56(11)：1934-1935+1941.
19	谢佩倍．赖氨葡锌颗粒对感染性腹泻患儿疗效与安全性的影响[J]．中国当代医药，2022，29(3)：95-98.
20	李伟．赖氨葡锌颗粒辅助治疗小儿轮状病毒性肠炎腹泻效果及对其炎性反应影响观察[J]．中外女性健康研究，2019(7)：87-88.

组别	例数	性别[例(%)]		年龄(岁，±s)	体重(kg，±s)	病程(d)	致病因素[例(%)]
组别	例数	男	女	年龄(岁，±s)	体重(kg，±s)	病程(d)	急性期未治愈	营养不良	肠道菌群失调	其它
对照组	70	36 (51.43)	34 (48.57)	1.27±0.25	7.62±1.23	24±1.65	36 (51.43)	12 (17.14)	17 (24.26)	5 (7.14)
观察组	70	33(47.14)	37 (52.86)	1.56±0.32	8.62±1.12	25±1.24	33(47.14)	15(21.43)	18(25.71)	4 (5.71)
t/χ²值		0.257		0.629	0.891	0.541	0.603
P值		0.612		0.156	0.374	0.242	0.896

组别	例数	性别[例(%)]		年龄(岁，±s)	体重(kg，±s)	病程(d)	致病因素[例(%)]
组别	例数	男	女	年龄(岁，±s)	体重(kg，±s)	病程(d)	急性期未治愈	营养不良	肠道菌群失调	其它
对照组	70	36 (51.43)	34 (48.57)	1.27±0.25	7.62±1.23	24±1.65	36 (51.43)	12 (17.14)	17 (24.26)	5 (7.14)
观察组	70	33(47.14)	37 (52.86)	1.56±0.32	8.62±1.12	25±1.24	33(47.14)	15(21.43)	18(25.71)	4 (5.71)
t/χ²值		0.257		0.629	0.891	0.541	0.603
P值		0.612		0.156	0.374	0.242	0.896

组别	例数	腹痛腹泻改善时间	大便性状恢复正常时间	食欲不振消失时间	住院时间
对照组	70	9.35±0.36	5.22±0.42	6.94±0.51	10.51±0.31
观察组	70	8.03±0.81	4.54±0.19	5.39±0.11	9.84±0.46
t值		7.115	12.531	16.023	15.644
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	腹痛腹泻改善时间	大便性状恢复正常时间	食欲不振消失时间	住院时间
对照组	70	9.35±0.36	5.22±0.42	6.94±0.51	10.51±0.31
观察组	70	8.03±0.81	4.54±0.19	5.39±0.11	9.84±0.46
t值		7.115	12.531	16.023	15.644
P值		<0.001	<0.001	<0.001	<0.001

组别	例数	IgM(g/L)		IgG(g/L)		IgA(g/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	70	0.62±0.41	0.81±0.22^a	7.36±1.29	8.02±1.23^a	0.41±0.14	0.68±0.10^a
观察组	70	0.51±0.52	0.92±0.11^ab	7.28±1.30	8.93±1.51^ab	0.50±0.15	0.85±0.12^ab
t值		0.265		0.614		1.003
P值		<0.001		<0.001		<0.001

Please choose a citation manager

Content to export